ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Has Consensus Price Target of $25.00

Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) have been given a consensus rating of “Moderate Buy” by the six research firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $25.00.

SPRY has been the subject of several recent research reports. Leerink Partners set a $15.00 price target on ARS Pharmaceuticals in a report on Tuesday, September 8th. Weiss Ratings downgraded ARS Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, August 17th.

ARS Pharmaceuticals Stock Performance

Shares of SPRY opened at $3.38 on Monday. The company has a market cap of $336.14 million, a price-to-earnings ratio of -1.55 and a beta of 0.98. The business’s fifty day simple moving average is $4.57 and its two-hundred day simple moving average is $7.42. ARS Pharmaceuticals has a 12 month low of $3.34 and a 12 month high of $13.15. The company has a current ratio of 3.48, a quick ratio of 3.28 and a debt-to-equity ratio of 13.72.

ARS Pharmaceuticals (NASDAQ:SPRY) last posted its earnings results on Thursday, August 13th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.15). ARS Pharmaceuticals had a negative net margin of 184.24% and a negative return on equity of 256.67%. The firm had revenue of $33.66 million during the quarter, compared to the consensus estimate of $31.32 million. Research analysts anticipate that ARS Pharmaceuticals will post -1.91 earnings per share for the current fiscal year.

Institutional Trading of ARS Pharmaceuticals

A number of large investors have recently made changes to their positions in the business. USAdvisors Wealth Management LLC bought a new position in ARS Pharmaceuticals during the 3rd quarter valued at about $43,000. WINTON GROUP Ltd bought a new stake in shares of ARS Pharmaceuticals during the 2nd quarter worth approximately $264,000. Engineers Gate Manager LP grew its position in ARS Pharmaceuticals by 195.0% in the 2nd quarter. Engineers Gate Manager LP now owns 139,419 shares of the company’s stock valued at $1,117,000 after acquiring an additional 92,163 shares during the last quarter. Allianz Asset Management GmbH bought a new position in ARS Pharmaceuticals in the 2nd quarter valued at $82,000. Finally, Corient Private Wealth LP lifted its position in shares of ARS Pharmaceuticals by 12.5% during the second quarter. Corient Private Wealth LP now owns 91,042 shares of the company’s stock worth $729,000 after purchasing an additional 10,099 shares during the last quarter. 68.16% of the stock is currently owned by institutional investors.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc (NASDAQ: SPRY) is a biopharmaceutical company focused on developing and commercializing treatments for severe allergic reactions. The company’s lead product is neffy (epinephrine nasal spray), a needle-free alternative to injectable epinephrine designed for the emergency treatment of allergic reactions, including anaphylaxis.

Neffy was approved by the U.S. Food and Drug Administration in 2024 for adults and pediatric patients who weigh at least 30 kilograms. The product is intended to provide rapid, convenient administration without requiring a syringe or injector, which may help address barriers associated with the use of traditional epinephrine auto-injectors.